Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kobayashi, H.
Right arrow Articles by Hattori, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kobayashi, H.
Right arrow Articles by Hattori, N.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 126, No. 1, 32-42, January 2003
© 2003 Guarantors of Brain
doi: 10.1093/brain/awg010

Haploinsufficiency at the {alpha}-synuclein gene underlies phenotypic severity in familial Parkinson’s disease

Hirokazu Kobayashi1, Rejko Krüger3, Katerina Markopoulou5, Zbigniew Wszolek7, Bruce Chase6, Hikaru Taka2, Reiko Mineki2, Kimie Murayama2, Olaf Riess4, Yoshikuni Mizuno1 and Nobutaka Hattori1

1 Department of Neurology and 2 Division of Biochemical Analysis, Juntendo University School of Medicine, Tokyo, Japan, Departments of 3 Neurology and 4 Medical Genetics, University of Tübingen, Tübingen, Germany, 5 Department of Neurological Sciences, University of Nebraska Medical Center and 6 Department of Biology, University of Nebraska at Omaha, Omaha, and 7 Department of Neurology, Mayo Clinic Jacksonville, USA

Correspondence to: Nobutaka Hattori, MD, Department of Neurology Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113-8421, Japan E-mail: nhattori{at}med.juntendo.ac.jp

To date, two point mutations, G209A and G88C, have been reported in the coding region of the {alpha}-synuclein gene in autosomal dominant familial Parkinson’s disease. When translated, these lead to the missense mutations Ala53Thr and Ala30Pro, respectively. Reduced mRNA expression of the G209A allele was reported recently in a Greek–American family. Here, we show that {alpha}-synuclein mRNA is normally expressed in blood cells and report the results of an analysis of {alpha}-synuclein mRNA and protein expression in lymphoblastoid cell lines established from kindreds with the G209A and G88C mutations. mRNA expression was characterized using a TaqMan real-time quantitative reverse transcriptase–polymerase chain reaction (RT–PCR) assay. We assessed five affected and three unaffected members of a German family with the G88C mutation and two affected members in different, unrelated Greek families with the G209A mutation. The ratio of wild-type to mutant {alpha}-synuclein allele expression ranged from 2.2 to 9.2 in the affected individuals with a severe clinical phenotype. The ratios of the expression levels of the wild-type to mutant alleles were only slightly decreased in mild cases and were less than 1.0 in two asymptomatic heterozygotes. Sequence analysis of the RT–PCR products showed only the presence of G in position 88 and G in position 209 in severely affected heterozygotes of the German and Greek families, respectively. High performance liquid chromatography/mass spectrometry demonstrated that, relative to wild-type {alpha}-synuclein, there is a reduction of Ala30Pro {alpha}-synuclein in lymphoblastoid cell lines originating from severely affected, but not mildly affected G88C/+ heterozygotes. Taken together, these data indicate that there is haploinsufficiency at the {alpha}-synuclein gene and that the ratio of expression of the wild-type to mutant alleles correlates with the severity of the clinical phenotype. Furthermore, these findings suggest that haploinsufficiency of {alpha}-synuclein mutations may contribute to disease progression in these forms of familial Parkinson’s disease.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
NeurologyHome page
P. Corcia, W. Camu, J. -M. Halimi, P. Vourc'h, C. Antar, S. Vedrine, B. Giraudeau, B. de Toffol, C. R. Andres, and for The French ALS Study Group
SMN1 gene, but not SMN2, is a risk factor for sporadic ALS
Neurology, October 10, 2006; 67(7): 1147 - 1150.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
S M Hague, S Klaffke, and O Bandmann
Neurodegenerative disorders: Parkinson's disease and Huntington's disease
J. Neurol. Neurosurg. Psychiatry, August 1, 2005; 76(8): 1058 - 1063.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
M. Ezquerra, J. Campdelacreu, E. Munoz, E. Tolosa, and M. J. Marti
A Novel Intronic Mutation in the DDP1 Gene in a Family With X-linked Dystonia-Deafness Syndrome
Arch Neurol, February 1, 2005; 62(2): 306 - 308.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
S. Gispert, C. Trenkwalder, L. Mota-Vieira, V. Kostic, and G. Auburger
Failure to Find {alpha}-Synuclein Gene Dosage Changes in 190 Patients With Familial Parkinson Disease
Arch Neurol, January 1, 2005; 62(1): 96 - 98.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
E. K. Tan, A. Chai, Y. Y. Teo, Y. Zhao, C. Tan, H. Shen, V. R. Chandran, M. L. Teoh, Y. Yih, R. Pavanni, et al.
Alpha-synuclein haplotypes implicated in risk of Parkinson's disease
Neurology, January 13, 2004; 62(1): 128 - 131.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.